Get the Stockscreener App
2.3399
8.37%
+0.1899
Revelation Biosciences Inc stock is currently priced at $2.3399, with a 24-hour trading volume of 39,588.
It has seen a +8.37% increased in the last 24 hours and a -10.04% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.15 pivot point. If it approaches the $2.37 resistance level, significant changes may occur.
Previous Close:
$2.15
Open:
$2.23
24h Volume:
39,588
Market Cap:
$3.51M
Revenue:
-
Net Income/Loss:
$-120.30K
P/E Ratio:
-4.2536
EPS:
-0.5501
Net Cash Flow:
$-7.29M
1W Performance:
+8.88%
1M Performance:
-10.04%
6M Performance:
+292.78%
1Y Performance:
+134.64%
1D Range:
$2.1606
$2.38
52W Range:
$0.277
$25.26
Revelation Biosciences Inc Stock (REVB) Company Profile
Name
Revelation Biosciences Inc
Sector
Industry
Phone
650 800 3717
Address
4660 La Jolla Village Drive, Suite 100, San Diego
Revelation Biosciences Inc Stock (REVB) Latest News
Top 5 Health Care Stocks That Are Preparing To Pump In February
Benzinga
Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Why Meta Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Benzinga
Dow Jumps 250 Points; Honeywell Issues Weak Forecast
Benzinga
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Crude Oil Gains 1%; ISM Manufacturing PMI Tops Expectations
Benzinga
Revelation Biosciences Inc Stock (REVB) Financials Data
Revelation Biosciences Inc (REVB) Net Income 2024
REVB net income (TTM) was -$120.30 thousand for the quarter ending December 31, 2023, a +98.89% increase year-over-year.
Revelation Biosciences Inc (REVB) Cash Flow 2024
REVB recorded a free cash flow (TTM) of -$7.29 million for the quarter ending December 31, 2023, a +35.06% increase year-over-year.
Revelation Biosciences Inc (REVB) Earnings per Share 2024
REVB earnings per share (TTM) was -$211.15 for the quarter ending December 31, 2023, a +70.35% growth year-over-year.
Revelation Biosciences Inc Stock (REVB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TIDMARSH GEORGE F | Director |
Oct 16 '23 |
Sale |
0.66 |
10,957 |
7,243 |
42,096 |
| TIDMARSH GEORGE F | Director |
Oct 16 '23 |
Sale |
0.65 |
1,845 |
1,199 |
27,771 |
| TIDMARSH GEORGE F | Director |
Sep 28 '23 |
Sale |
0.69 |
1,429 |
986 |
42,096 |
| TIDMARSH GEORGE F | Director |
Sep 18 '23 |
Sale |
0.74 |
4,000 |
2,960 |
39,348 |
| TIDMARSH GEORGE F | Director |
Sep 15 '23 |
Sale |
0.73 |
9,500 |
6,935 |
43,348 |
| TIDMARSH GEORGE F | Director |
Sep 14 '23 |
Sale |
0.75 |
12,000 |
9,000 |
52,848 |
About Revelation Biosciences Inc
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
1.27%
4.42%
Cap:
|
Volume (24h):